Pharmacology and quantitative structure-activity relationships of imidazolylpropylguanidines with mepyramine-like substructures as non-peptide neuropeptide Y Y1 receptor antagonists

Canadian Journal of Physiology and Pharmacology

Volumn 78, Issue 2, 2000, Pages 108-115

  Dove, Stefan ^a   Michel, Martin C ^b   Knieps, Sebastian ^a   Buschauer, Armin ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Imidazolylpropylguanidines; Neuropeptide Y Y1 antagonists; Quantitative structure activity relationships

Indexed keywords

ARPROMIDINE; CALCIUM ION; GUANIDINE DERIVATIVE; HISTAMINE H2 RECEPTOR AGONIST; MEPYRAMINE; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NITROGEN; PHENIRAMINE; PHENYL GROUP;

ARTICLE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG STRUCTURE; ERYTHROLEUKEMIA CELL; HUMAN; HUMAN CELL; HYDROPHOBICITY; PRIORITY JOURNAL; REGRESSION ANALYSIS; STRUCTURE ACTIVITY RELATION;

EID: 0034012507     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y99-120     Document Type: Article

References (31)

1. Allen, J.M., Novotny, J., Martin, J., and Heinrich, G. 1987. Molecular structure of mammalian neuropeptide Y: analysis by molecular cloning and computer-aided comparison with crystal structure of avian homologue. Proc. Natl. Acad. Sci. U.S.A. 84: 2532-2536.
2. 2 receptors. Biopolymers, 37: 123-142.
3. 2 receptors with distinguished conformations. Eur. J. Biochem. 225: 947-958.
4. Buschauer, A. 1989. Synthesis and in vitro pharmacology of arpromidine and related phenyl-(pyridylalkyl)guanidines, a potential new class of positive inotropic drugs. J. Med. Chem. 32, 1963-1970.
5. 2 agonists. Eur. Pat. Appl. EP 0199845.
6. Free, S.M. Jr., and Wilson, J.W. 1964. A mathematical contribution to structure-activity studies. J. Med. Chem. 7: 395-399.
7. Fujita. T., and Ban, T. 1971. Structure-activity study of phenethylamines as substrates of bio-synthetic enzymes of sympathetic transmitters. J. Med. Chem. 14: 148-152.
8. Gehlert, D.R. 1994. Subtypes of receptors for neuropeptide Y: implications for the targeting of therapeutics. Life Sci. 55: 551-562.
9. Glover, I., Haneef, I., Pitts, J., Wood, S., Moss, D., Tickle, I., and Blundell, T. 1983. Conformational flexibility in a small globular hormone: x-ray analysis of avian pancreatic polypeptide at 0.98-Å resolution. Biopolymers, 22: 293-304.
10. 1 antagonists. J. Med. Chem. 40: 3712-3714.
11. 1-Antagonisten. Doctoral thesis, Freie Universität Berlin.
12. 2 agonist arpromidine: Role of the guanidino group. Bioorg. Med. Chem. Lett. 5: 2065-2070.
13. Knieps, S., Dove, S., Michel, M.C., Rottmeier, K., Wernet, W., Bernhardt, G. and Buschauer, A. 1996. ω-Phenyl-ω-(2-pyridyl)alkyl substituted bisguanidines are moderate neuropeptide Y antagonists. Pharm. Pharmacol. Lett. 6: 27-30.
14. Kubinyi H. 1990. Quantitative Drug Design. In Vol. 4 of Comprehensive Medicinal Chemistry. The Rational Design. Edited by C. Hansch, P.G. Sammes, and J.B. Taylor. Pergamon Press, Oxford.
15. Michel, M.C. and Motulsky, H.J. 1990. He 90481: a competitive nonpeptidergic antagonist at neuropetide Y receptors. Ann. N.Y. Acad. Sci. 611: 392-394.
16. 2 agonists as chemical leads for the development of non-peptide neuropeptide Y antagonists. Arch. Pharm. (Weinheim), 326: 664.
17. Michel, M.C., Beck-Sickinger, A., Cox, H., Doods, H.N., Herzog, H., Larhammar, D., Quirion, R., Schwartz, T., and Westfall, T. 1998. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic poly-peptide receptors. Pharmacol. Rev. 50: 143-150.
18. 2-agonists. Drugs Future. 15: 919-933.
19. 2+ and inhibits adenylate cyclase in human erythroleukemia cells. Am. J. Physiol. 255: E880-885.
20. 1 receptor antagonistic activity of N,N-disubstituted ω-guanidino-and ω-aminoalkanoic acid amides. Arch. Pharm. (Weinheim), 330: 333-342.
21. Munglani, R., Hudspith, M.J., and Hunt, S.P. 1996. The therapeutic potential of neuropeptide Y. Analgesic, anxiolytic and antihypertensive. Drugs, 52: 371-389.
22. 1 receptor investigated by site-directed mutagenesis and molecular modeling. Mol. Cell. Endocrinol. 139: 187-198.
23. 1 receptor antagonist: BIBP3226. Eur. J. Pharmacol. 271: R11-13.
24. 1 neuropeptide Y receptor in ligand binding. Mol. Cell. Endocrinol. 112: 215-222
25. 1 receptor antagonist. FEBS Lett. 362: 192-196.
26. 2-agonistic properties; synthesis, in vitro pharmacology and structure-activity relationships. Eur. J. Med. Chem. 22: 491-498.
27. Tatemoto, K., Carlquist, M., and Mutt, V. 1982. Neuropeptide Y: a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature (London), 296: 659-660.
28. Uffrecht, A., Wernet, W., Unger, L., Dove, S., and Buschauer, A. 1994. In search of non-peptide NPY antagonists - replacement of the imidazole ring in arpromidine analogs. Eur. J. Pharm. Sci. 2: 137.
29. 1 neuropeptide Y receptor are essential for ligand binding. J. Biol. Chem. 269: 2863-2869.
30. 1 receptor antagonists. J. Med. Chem. 41: 2709-2719.
31. 1 receptor antagonists. Bioorg. Med. Chem. Lett. 8: 473-476.